Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Pharm > HIV > Flashcards

HIV Flashcards

1
Q

Human immunodeficiency virus

HIV

A
  1. HIV-1- most common type with AIDS- most tx target
  2. HIV-2- mostly West africa and india

Main target- immune system- immunodeficiency
cd4, helper t cells, macrophages, dendritic cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

HIV diagnoses over time

A

17% decrease in 2020 bc no one was going to the doctor
* gay, bisexual, msm contact= main population affectd

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

HIV mech

A
  1. HIV infects cells by using the CD4 molecule as a receptor and various chemokine receptors as coreceptors. MUST also bind to these coreceptors for entry into the cell. Fusion w/ CD4 and gp120
  2. The gp120 envelope glycoprotein binds to CD4, which leads to conformational change that produces a new recognition site on gp120 for those coreceptors (induces changes in gp41 that expose the fusion peptide).
  3. The peptide inserts into the cell membrane of the target cells leading to the fusion of the virus and host cell. Virus core containing the HIV genome is able to enter the cell. hiv reverse transcriptase, integrase, and other viral proteins, enter cell
  4. Once it enters the cell, the RNA genome undergoes reverse transcription and leads to double stranded complementary DNA. Integrates into the host DNA. It can stay silent for months or years or form new viral RNA and proteins. viral dna formed by reverse transcripton then transported and integrated into host dna
  5. In the case of most CD4+ T cells, viral replication and shedding leads to cell lysis. viral rna and proteins move to surface and released
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

1 assoc symptom with HIV

A

Kaposi sarcoma- tongue
Raised erythematous - Herpes 8

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Antiretroviral therapy

ART therapy

A

Each class targets a different step in life cycle:
use of agents in clinic is dictated by:
* ease of use
* SE
* efficacy based on clinical evidence
* clinician and pt preference
* resistance, AE, Pregnancy, infection with Hep B and C

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Drug classes for ART therapy

A
  1. Non nucleoside reverse transcriptase inhibitors (NNRTIs)
  2. Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)
  3. Protease inhibitors

others: fusion inhibitor, entry inhibitors, integrase strand transfer inhibitors

COMBOS IS HALLMARK OF TX

KNOW NUMBERED

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Drug classes for ART therapy

A
  1. Non nucleoside reverse transcriptase inhibitors (NNRTIs)
  2. Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)
  3. Protease inhibitors

others: fusion inhibitor, entry inhibitors, integrase strand transfer inhibitors

COMBOS IS HALLMARK OF TX

KNOW NUMBERED

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Non nucleoside reverse transcriptase inhibitors NNRTIS

A

Efavirenz and Nevirapine
MOA: bind directly to HIV1 reverse transcriptase-> allosteric inhibition of RNA and dna dependent dna polymerase activity
2nd gen= higher potency, and reduced SE (Doravirine, etravirin vs. Delavirdine, efavirenz)
Testing: genotypi testing since there could be primary resistance
No cross resistance btwn NNRTI and NRTIS

ALL ARE SUBSTRATES FOR CYP3A4-> can be inducers, inhibitors, or mixed

binding site differ from NRTIS-> doesnt compete with triphosphates

or need active phosphorylation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Efavirenz

nnrtis

A

SE: neuropsychiatric sxs: insomnia, vivid dreaming, dizziness, confusion, hallucinations
NO PREGO

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Nevirapine

nnrtis

A

Severe rash, hepatitis- occasionally fulminant and fatal
macular papular can lead to SJS or life threatening hepatitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Nucleoside/nucleotide reverse transcriptase inhibitors

NRTIS

A

Tenofovir Alafenamide TAF, Didanosine (Videx), Stavudine, Tenofovir disoproxil fumarate (TDF)-Vemlidy
MOA: interrupts HIV rep via competitive inhibition of reverse transcriptase= termination of DNA chain
SE: mitochondrial toxicity -> peripheral neuropathy, lactic acidosis can be fatal= Sodium bicarb tx

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Tenofovir alafenamide TAF

nrti

bolded

A

TAF
SE: GI symptoms, headache, increased creatinine, proteinuria, bone loss

all less than TDF

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Tenofovir disoproxil fumarate TDF

Vemlidy

A

SE: n.v.d flatulence, headache, renal insuff, bone loss

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Abacavir

NRTI

Ziagen

A

Test to rule out HLAB-27 prior bc increased hypersensitivity reactions
SE: possible increase in MI, rash, hypersens reaction, nausea
avoid alcohol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Didanosine (Videx)

nrti

A

SE: peripheral neuropathy, pancreatitis, diarrhea

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Stavudine

nrti

A

SE: peripheral neuropathy, pancreatitis, rapid neuromusc weakness- rare

16
Q

Zidovudine (AZT) (Retrovir)

A

SE: macrocytic anemia, neutropenia, nausea, headache, insomnia
Avoid: concurrent with Stavudine and mylosuppressive drugs (ganciclovir or ribavirin)
Can be used pediatrics

17
Q

Protease inhibitors PIS

A

Atazanavir, Indinavir
MOA: prevent processing of viral proteins into functional conformations-> produce immature or noninfectious viral particles
Genotypic alterations-> resistence so MONOTHERAPY NOT REC
SE: GI INTOLERANCE- NVD
lipodystrophy-> hyperglycemia/hyperlipidemia-> may require lipid lowering agents
syndrome of tredistrubution and accum body fat-> specifically w/ nrtis- central obesity, dorsocervical fat enlargemetn (buffalo hump), peripheral facial wasting, breast enlargment, cushingoid appearance
cardiac conduction abn: PR and AT elongation
Metab via CYP3a4

18
Q

Atazanavir

PIS

A

SE: Nausea, rash indirect hyperbilirubinemia, diarrhea, elevated liver enzymes

19
Q

Indinavir

PSI

A

SE: Nephrolithiasis, indirect hyperbilirubinemia, nausea, diarrhea, headache, possible MI

20
Q

Fusion Inhibitors

A

Enfuvirtide
MOA: blocks HIV entry into cell-> binds gp41 subunit of viral envelope glycoprotein
SQ injxn: ONLY ANTIRETROVIRAL LIKE THIS
AE: local injxn site rxn, potential: insomnia, headache, nd, eosinophilia, increased bacterial pneumonia
NO SIGNIFICANT DRUGDRUG INTERACTIONS

21
Q

Entry inhibitors

A
  1. Idalizumab- monoclonal ab that binds CD4 receptor and blocks HIV entry- FOR MULTIDRUG RESIS HIV- CAN BE IN COMBO- nvd
  2. Maraviroc-CCR5-tropic HIV1- binds to CCR5
    SE: cough, pyrexia (fever), rash, hepatitis
22
Q

Integrase strand transfer inhibitors

INSTIS

A
  1. Bictegravir
  2. Dolutegravir
  3. Elvitegravir
  4. Raltegravir
    MOA: binds to integrase-> inhibits ssstrand stransfer thus interfering with integration into host dna
    AE: n/v, CK/LFT elevations, headache
    First line regimen-> bc high genetic barrier to resistance
    DECREASES VIRAL LOAD MORE RAPIDLY THAN ANY OTHER ART
23
Q

Clinical approach to HIV tx

A
  • risk- benefit
  • cost
  • adherence- once begun, tx is forever
  • pill burdern- try to fix by once a day
  • patient readiness trumps cd4 count
  • high risk pts should begin tx regardless of count symptomatic, pregnant, liver disease, high viral load
  • Naive vs non naive patients
24
Q

Recommendations for HIV

A
  1. ART should be initiated in all adults living with HIV- regardless of count or stage
  2. PRIORITY- all adults with severe or advanced (stage 3 or 4) (count equal or below 350
  3. ALL PREGNANT AND BREASTFEEDING WOMEN LIVING WITH HIV
  4. ALL CHILDREN LIVING WITH HIV
25
Q

ART: antiretroviral therapy

rules

A

Usual therapy is 3 or more combos:
* 2x NRTIS plus a INSTI or NNRTI or PI with pharmacokinetic enhancer

2 drug regimen: Dolutegravir + Lamivudine
* reduces viral load till undetectable
* Cautious with antiherpetics
* GI, fatigue, cns, fatty liver sx improve after 1 month

26
Q

Possible initial tx regimens innaive pt

A
  1. Biktarvy: Bictegravir/tenofovir alafenamide/Emtricitabine
  2. Dovato: Dolutegravir/Lamivudine
27
Q

Biktarvy

Bictegravir/Emtricitabine/Tenogovir alafenamid

A

BBW: severe acute exacerbations of hepatitis B
BUT ONE PILL A DAY
AE: nd, headache

28
Q

Dovato

dolutegravir/lamivudine

A

AE: headache, nd, trouble sleeping, tiredness, anxiety

29
Q

Agents added to initial regimen

if viral load not going down

A
  1. Atazanivir (PI) (reyataz)- careful with Statins, SE: GI, CNS, IRS, metabolic
  2. Darunivir (PI) (prezista)
  3. Raltegravir (II)- low drug interactions: GI, headache, fever
  4. Maraviroc (CCR5 co-R antag)- cough and fever
30
Q

pharmacokinetic enhancers

boosting agents

A
  1. Cobicistat= CYP3A inhibitor- increases systemic exposure
  2. Ritonavir= CYP3A4- in many combo products to augment systemic exposure
31
Q

Goals of tx:

A

<reduce HIV infxn- morbidity, prolong survival
< improve quality of life
< restore and preserve immunologic fxn
<maximally suppress viral load
<prevent vertical HIV transmission

32
Q

Immune reconstitution inflammatory syndrome

A
  • inflammatory rxn occurs after initiation of antiretroviral tx- secondary to rapid increase in CD4 count
  • SXS: fevers, sweats, malaise, unusual presentations of opportunistic infxn
  • cmv retinitis- vitreitis
  • M. avium- focal, suppurative lymphadenitis
  • TB- worsen new with new pulmonary infiltrates
  • diag: of exclusion
  • TX: conservative and supportive with corticosteroids for severe
  • CONTINUE ART THERAPY UNLESS LIFE THREATENING

high ag load + immune cell dysfunction + ART initiation= excess proinflammatory cytokine activity-> IRIS

33
Q

hiv + tb+ART

A

cause giant lymphnode swellings? that will go away

34
Q

Pregnancy and HIV

A
  1. NRTIS
    * abacavir
    * emtricitabine
    * lamivudine
    * Tenofovir disoproxil fumarate
    * zidovudine= alternative= iv during labor
  2. PI
    * atazanavir/ritonavir
    * darunavir/ritonavir
  3. II- Dolutegravir should not be used in 1st trimester due to possible increased risk of neural tube defects
35
Q

Pre exposure prophylaxis

PREP

A

To prevent sexual acquisition of HIV
RF: MSM, promiscuous heterosexual, sexually active transgender, IV drug use
Truvada= emtricitabine and tenofovir disoproxil fumarate
Descovy= emtricitabine and tenofovir alafenamide

36
Q

Post exposure prophylax for health care workers

A

intact skin or urine source do not need PEP
must be started w.in 72 hours-> risk of transmission from needle stick with blood from hiv pt is 1:300

HIV 3-drug PEP regimen- given 28 days
1. Raltegravir
2. Dolutegravir (DTG)
3. Truvada

testing at: 0, 6, 12 weeks

37
Q

Post exposure prophylaxis: non occupational

A

28 days
1. Tenofovir w/
2. emtricitabine
3. either Raltegravir or Dolutegravir

38
Q

Summary

A
  1. list 6 classes of HIV TX
  2. details of clinical approach to HIV TX
  3. basics of ART
  4. 2 drug combos w NRTI tx
  5. SE and interactions for ART
  6. Boosting agents and rationale for use
  7. immune reconstitution syndrome explain-> clinical relevance
  8. Basics of post exposure prophylaxis for HIV

Pharm (9 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions